Akebia Therapeutics/AKBA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Ticker

AKBA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Cambridge, United States

Employees

167
Website
akebia.com

AKBA Metrics

BasicAdvanced
$235M
Market cap
-
P/E ratio
-$0.22
EPS
0.79
Beta
-
Dividend rate
$235M
0.79
$2.48
$0.78
107
1.699
1.315
-4.82%
-17.13%
-24.39%
1.254
-30.69%
33.96%
-12.91%

What the Analysts think about AKBA

Analyst Ratings

Majority rating from 3 analysts.
Buy

AKBA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-54.90% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$33M
-41.89%
Net income
-$18M
-3,083.33%
Profit margin
-54.90%
-5,279.25%

AKBA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 17.39%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.06
-$0.08
-
-$0.09
-
Expected
-$0.03
-$0.09
-$0.04
-$0.08
-$0.05
Surprise
140.00%
-5.88%
-
17.39%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Akebia Therapeutics stock?

Akebia Therapeutics (AKBA) has a market cap of $235M as of June 24, 2024.

What is the P/E ratio for Akebia Therapeutics stock?

The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of June 24, 2024.

Does Akebia Therapeutics stock pay dividends?

No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of June 24, 2024.

When is the next Akebia Therapeutics dividend payment date?

Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.

What is the beta indicator for Akebia Therapeutics?

Akebia Therapeutics (AKBA) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Akebia Therapeutics stock price target?

The target price for Akebia Therapeutics (AKBA) stock is $5, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Akebia Therapeutics stock

Buy or sell Akebia Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing